Divi''s Lab
Ticker >

Divi''s Lab share price

Divi''s Laboratories Ltd.

NSE: DIVISLAB BSE: 532488 SECTOR: Pharmaceuticals & Drugs  295k   2k   651

3765.15
+100.15 (2.73%)
NSE: 29 Sep 03:57 PM

Price Summary

Today's High

₹ 3784

Today's Low

₹ 3687

52 Week High

₹ 3934.7

52 Week Low

₹ 2730

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 99952.9 Cr.

Enterprise Value

₹ 95765.34 Cr.

No. of Shares

26.55 Cr.

P/E

68.39

P/B

7.66

Face Value

₹ 2

Div. Yield

0.8 %

Book Value (TTM)

₹  491.6

CASH

₹ 4187.56 Cr.

DEBT

₹ 0 Cr.

Promoter Holding

51.93 %

EPS (TTM)

₹  55.06

Sales Growth

-14.13%

ROE

14.82 %

ROCE

19.31%

Profit Growth

-38.68 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Index Presence

The company is present in 33 Indices.

NIFTYEQWGT

NIFTY50 Equal Weight
23566.35
  210.399999999998 (0.900841113292317%)

NIFTY100WEIGHT

Nifty100 Equal Weight
23177.65
  210.5 (0.916526430140441%)

NIFTY

Nifty 50
19638.3
  114.75 (0.587751715236218%)

NIFTY100

Nifty 100
19577.05
  125.399999999998 (0.644675387434979%)

NIFTY500

Nifty 500
17292.6
  122.149999999998 (0.711396614532522%)

NIFTY200QLTY30

NIFTY200 Quality 30
16391.8
  127.349999999999 (0.782996043518214%)

NIFTYPHARMA

Nifty Pharma
15422.75
  399.6 (2.65989489554455%)

NFTQTLO30

NIFTY Quality Low-Volatility 30
14112.59
  60.5799999999999 (0.431112702026248%)

NIFTYLGEMID250

NIFTY LargeMidcap 250
11877.5
  99.1499999999996 (0.84179872392991%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
11821.05
  87.6499999999996 (0.747012801063618%)

NIFTY200

Nifty 200
10510.25
  74.1000000000004 (0.710031956229074%)

NIFTYMFG

Nifty Manufacturing
9796.8
  122.5 (1.26624148517205%)

NIFTYHEALTH

Nifty Healthcare Index
9719.05
  242.949999999999 (2.56381844851783%)

NIFTYTOTALMCAP

Nifty Total Market index
9702.5
  68.5499999999993 (0.711546146699948%)

NIFTY500VAL50

NIFTY500 Value 50
9072.76
  36.4400000000005 (0.403261504683328%)

SHARIAH25

Nifty Shariah 25
6824.74
  13.6199999999999 (0.199967112604083%)

NSEQ30

NIFTY100 Quality 30
4432.85
  22.3500000000004 (0.506745266976538%)

NIFTY100ESG

NIFTY100 ESG
3726
  18.4499999999998 (0.497633207913584%)

BSE HC

S&P Bse Healthcare
28497.52
  618.350000000002 (2.21796416464335%)

BSE500

S&P Bse 500
27407.75
  194.220000000001 (0.713689109792082%)

SNSX50

S&P Bse Sensex50
20591.26
  123.579999999998 (0.603781180866614%)

BSE100

S&P Bse 100
20123.3
  130.899999999998 (0.654748804545724%)

BSE200

S&P Bse 200
8613
  61.4799999999996 (0.718936516549107%)

LMI250

S&P Bse 250 LargeMidCap
8162.68
  57.7700000000004 (0.712777809994192%)

S&P LARGEMIDCAP

S&P Bse Large MidCap
8045.61
  -84.4200000000001 (-1.03837255213081%)

ALLCAP

S&P Bse Allcap
7961.13
  56.75 (0.717956373554918%)

LRGCAP

S&P Bse LargeCap
7462.57
  46.6300000000001 (0.628780707503029%)

BSE100LARGECAPTMC

S&P Bse 100 LargeCap TMC
7129.5
  44.1099999999997 (0.622548652932298%)

GREENEX

S&P Bse Greenex
5252.13
  42.2600000000002 (0.811152677514038%)

CARBONEX

S&P Bse Carbonex
3275.95
  22.7399999999998 (0.699001908883834%)

MFG

S&P Bse Manufacturing
806.77
  8.42999999999995 (1.0559410777363%)

S&PDIVSTABLE

S&P Bse Dividend Stability
725.25
  7.16999999999996 (0.998495989304815%)

ESG100

S&P Bse 100 ESG Index
321.48
  2.15000000000003 (0.673284689819309%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-14.13%
3 Year12.82%
5 Year14.85%

Profit Growth

1 Year-38.68%
3 Year9.62%
5 Year15.77%

ROE%

1 Year14.82%
3 Year22.17%
5 Year21.27%

ROCE %

1 Year19.31%
3 Year28.68%
5 Year27.87%

Debt/Equity

0

Price to Cash Flow

40.83

Interest Cover Ratio

1393.95857988166

CFO/PAT (5 Yr. Avg.)

0.900275784584311

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2023 51.93 0
Mar 2023 51.94 0
Dec 2022 51.94 0
Sep 2022 51.94 0
Jun 2022 51.94 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROE of 22.1737931650595% over the past 3 years.
  • Company has been maintaining healthy ROCE of 28.6817140208096% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 1393.95857988166.
  • The Company has been maintaining an effective average operating margins of 37.361910014032% in the last 5 years.
  • Company has a healthy liquidity position with current ratio of 6.40071638075438.
  • The company has a high promoter holding of 51.93%.

 Limitations

  • The company has shown a poor profit growth of 9.61884439493266% for the Past 3 years.
  • The company has shown a poor revenue growth of 12.8163208074344% for the Past 3 years.
  • The company is trading at a high PE of 68.39.
  • The company is trading at a high EV/EBITDA of 40.887.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023
Net Sales 2204 1823.38 1689.83 1908.17 1730
Total Expenditure 1367 1214.12 1280.41 1419.47 1239
Operating Profit 837 609.26 409.42 488.7 491
Other Income 90 79.25 116.34 66.15 80
Interest 0 0.13 0.11 0.18 0
Depreciation 83 85.48 86.54 86.63 93
Exceptional Items 0 0 0 0 0
Profit Before Tax 844 602.9 439.11 468.04 478
Tax 153 116.05 128.21 149.25 133
Profit After Tax 691 486.85 310.9 318.79 345
Adjusted EPS (Rs) 26.03 18.34 11.71 12.01 13.02

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 4879.66 5310.57 6798.61 8879.82 7625.3
Total Expenditure 3029.59 3494.16 3977.73 5005.05 5276.45
Operating Profit 1850.07 1816.41 2820.88 3874.77 2348.85
Other Income 156.58 189.86 63.45 114.03 349.01
Interest 4.61 7.03 1.81 1.73 1.69
Depreciation 168.81 185.95 254.65 310.55 342.07
Exceptional Items 0 0 0 0 0
Profit Before Tax 1833.23 1813.29 2627.87 3676.52 2354.1
Tax 500.58 440.58 673.15 727.98 545.95
Net Profit 1332.65 1372.71 1954.72 2948.54 1808.15
Adjusted EPS (Rs.) 50.2 51.71 73.64 111.08 68.12

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 53.09 53.09 53.09 53.09 53.09
Total Reserves 6920.22 7263.6 9218.48 11638.26 12652.33
Borrowings 0 0 0 0 0
Other N/C liabilities 993.72 294.48 363.48 448.11 567.83
Current liabilities 832.52 1796.64 1704.78 2427.29 1510.37
Total Liabilities 8799.55 9407.81 11339.83 14566.75 14783.62
Assets
Net Block 2087.44 2776.26 3699.01 4320.97 4718.76
Capital WIP 491.91 919.69 710.62 469.93 211.88
Intangible WIP 0 0 0 0 0
Investments 554.62 7.37 7.37 79.37 84.41
Loans & Advances 1012.93 144.18 172.42 133.58 97.47
Other N/C Assets 5.16 5.44 9.21 8.05 3.65
Current Assets 4647.49 5554.87 6741.2 9554.85 9667.45
Total Assets 8799.55 9407.81 11339.83 14566.75 14783.62
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 1833.23 1813.29 2627.87 3676.52 2354.1
Adjustment 86.71 52.55 186.66 235.32 118.14
Changes in Assets & Liabilities -472.96 -211.4 -234.52 -1371.89 447.3
Tax Paid -482.92 -445.97 -632.96 -629.79 -471.59
Operating Cash Flow 964.06 1208.47 1947.05 1910.16 2447.95
Investing Cash Flow -684.24 -81.38 75.34 -2195.4 -2706.75
Financing Cash Flow -245.94 -1091.25 -33.97 -531.5 -796.59
Net Cash Flow 33.88 35.84 1988.42 -816.74 -1055.39

Corporate Actions

Investors Details

PARTICULARS Jun 2022% Sep 2022% Dec 2022% Mar 2023% Jun 2023%
promoters 51.94 51.94 51.94 51.94 51.93
madhusudana rao divi 0.11 0.11 0.11 0.11 0.11
murali krishna prasad div... 2.85 2.85 2.85 2.85 2.85
nilima prasad divi 20.34 20.34 20.34 20.34 20.34
satchandra kiran divi 20.34 20.34 20.34 20.34 20.34
swarna latha divi 5.27 5.27 5.27 5.27 5.27
babu rajendra prasad divi... 0.01 0.01 0.01 0.01 -
PARTICULARS Jun 2022% Sep 2022% Dec 2022% Mar 2023% Jun 2023%
investors 48.06 48.06 48.06 48.06 48.07
axis mutual fund trustee ... 3.77 3.54 3.06 2.60 2.83
government pension fund g... 1.32 1.18 1.20 1.20 1.21
investor education and pr... - - - 0.01 0.01
life insurance corporatio... 3.71 4.69 5.53 5.55 5.70
sbi mutual fund 6.15 6.44 6.70 7.71 7.80
investor education and pr... - 0.01 0.01 - -
iepf 0.01 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Divi's Laboratories informs about closure of trading window30 Sep 2023, 3:45PM Divi's Laboratories informs about earnings call transcript19 Aug 2023, 2:31PM Divi's Laboratories informs about newspapers publication16 Aug 2023, 9:57AM Divi's Laboratories reports 49% fall in Q1 consolidated net profit14 Aug 2023, 2:30PM Divi's Lab - Quaterly Results14 Aug 2023, 12:55PM Divi's Lab - Quaterly Results14 Aug 2023, 12:55PM Divi's Lab - Quaterly Results14 Aug 2023, 12:55PM Divi's Laboratories informs about secretarial compliance report23 May 2023, 11:25AM Divi's Laboratories reports 64% fall in Q4 consolidated net profit22 May 2023, 12:44PM Divi's Lab - Quaterly Results20 May 2023, 1:28PM Divi's Lab - Quaterly Results20 May 2023, 1:28PM Divi's Lab - Quaterly Results20 May 2023, 1:28PM Divi's Laboratories informs about certificate 11 Apr 2023, 9:21AM Divi's Laboratories reports 66% fall in Q3 consolidated net profit3 Feb 2023, 3:19PM Divi's Lab - Quaterly Results3 Feb 2023, 12:51PM Divi's Lab - Quaterly Results3 Feb 2023, 12:51PM Divi's Lab - Quaterly Results3 Feb 2023, 12:51PM Divi’s Laboratories informs about conference call25 Jan 2023, 9:58AM Divi's Laboratories informs about trading window closure24 Dec 2022, 4:16PM Divi's Laboratories informs about newspaper publication24 Dec 2022, 12:06PM Divi's Laboratories reports 19% fall in Q2 consolidated net profit8 Nov 2022, 11:59AM Divi's Lab - Quaterly Results7 Nov 2022, 12:52PM Divi's Lab - Quaterly Results7 Nov 2022, 12:52PM Divi's Lab - Quaterly Results7 Nov 2022, 12:52PM Divi's Laboratories informs about board meeting28 Oct 2022, 3:37PM Divi's Laboratories reports 26% rise in Q1 consolidated net profit 12 Aug 2022, 4:53PM Divi's Lab - Quaterly Results12 Aug 2022, 12:26PM Divi's Lab - Quaterly Results12 Aug 2022, 12:26PM Divi's Lab - Quaterly Results12 Aug 2022, 12:26PM Divi's Laboratories informs about newspaper publication26 Jul 2022, 5:03PM Divi's Laboratories informs about press release20 Jul 2022, 5:17PM Divi’s Laboratories reports 78% rise in Q4 consolidated net profit23 May 2022, 2:38PM Divi's Lab - Quaterly Results23 May 2022, 12:20PM Divi's Lab - Quaterly Results23 May 2022, 12:20PM Divi's Lab - Quaterly Results23 May 2022, 12:20PM Divi's Laboratories informs about compliance report12 May 2022, 5:14PM Divi's Laboratories informs about non-applicability of large corporate12 Apr 2022, 9:29AM Divi’s Laboratories informs about newspaper advertisement26 Feb 2022, 3:14PM Divi's Laboratories reports 92% rise in Q3 consolidated net profit 11 Feb 2022, 2:15PM Divi's Lab - Quaterly Results11 Feb 2022, 11:59AM Divi's Lab - Quaterly Results11 Feb 2022, 11:59AM Divi's Lab - Quaterly Results11 Feb 2022, 11:59AM Divi’s Laboratories informs about earnings conference call3 Feb 2022, 4:56PM Divi's Laboratories submits certificate7 Jan 2022, 10:35AM Divi's Laboratories reports 17% rise in Q2 consolidated net profit8 Nov 2021, 9:30AM Divis Laboratories informs about outcome of board meeting6 Nov 2021, 12:50PM Divi's Lab - Quaterly Results6 Nov 2021, 11:48AM Divi's Lab - Quaterly Results6 Nov 2021, 11:48AM Divi's Lab - Quaterly Results6 Nov 2021, 11:48AM Divi’s Laboratories informs about earnings conference call2 Nov 2021, 9:53AM

Divi''s Lab Stock Price Analysis and Quick Research Report. Is Divi''s Lab an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Divi''s Lab and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 2447.95 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Divi''s Lab has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Divi''s Lab , the EPS growth was -38.6764136589933 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Divi''s Lab has OPM of 30.8033782277419 % which is a good sign for profitability.
     
  • ROE: Divi''s Lab have a average ROE of 14.8228638463206 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Last Updated on:
Brief about Divi''s Lab

Divi''s Laboratories Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

Divi's Laboratories Ltd. is a leading Indian pharmaceutical company that specializes in the production of active pharmaceutical ingredients (API) and intermediates. In this article, we will provide a comprehensive analysis of Divi's Laboratories Ltd.'s stock from a long-term investor's perspective. We will cover various topics such as share price, balance sheet, annual report, dividend, quarterly result, stock price, price chart, news, concall, transcripts, investor presentations, promoters, and shareholders.

Divi''s Laboratories Ltd. Share Price:

Divi's Laboratories Ltd.'s share price is one of the key indicators of investor sentiment towards the company. The share price is influenced by various factors such as the company's financial performance, global economic conditions, and market sentiment. Long-term investors can use our pre-built screening tools to analyze Divi's Laboratories Ltd.'s share price and identify any trends or patterns. The company's share price has shown a consistent upward trend over the past few years, reflecting the company's strong brand, product portfolio, and customer focus.

Divi''s Laboratories Ltd. Balance Sheet:

Divi's Laboratories Ltd.'s balance sheet provides crucial information about its financial health. The company's assets include fixed assets, investments, and inventory, while liabilities include borrowings and other liabilities. Equity includes share capital, reserves, and surplus. Long-term investors can use our pre-built screening tools to analyze Divi's Laboratories Ltd.'s balance sheet and identify any red flags. The company's balance sheet has been strong over the past few years, reflecting the company's ability to generate cash and manage its liabilities.

Divi''s Laboratories Ltd. Annual Report:

Divi's Laboratories Ltd. releases an annual report every year, which provides detailed information about the company's financial performance, strategic initiatives, and future plans. The annual report includes a letter from the Chairman, financial statements, and management discussion and analysis. Long-term investors can download Divi's Laboratories Ltd.'s annual report from our website and use it to make informed investment decisions. The annual report provides valuable insights into the company's operations and financial performance.

Divi''s Laboratories Ltd. Dividend:

Divi's Laboratories Ltd. pays dividends to its shareholders. The company has a consistent dividend policy and pays dividends regularly. Long-term investors should consider this when evaluating Divi's Laboratories Ltd.'s stock. Our pre-built screening tools can be used to analyze the company's dividend history and identify any trends or patterns.

Divi''s Laboratories Ltd. Quarterly Results:

Divi's Laboratories Ltd. releases its quarterly results every three months. The quarterly results provide information about the company's revenue, earnings, and expenses. Long-term investors can use our pre-built screening tools to analyze Divi's Laboratories Ltd.'s quarterly results and identify any trends or patterns. The quarterly results are an important indicator of the company's financial health and performance.

Divi''s Laboratories Ltd. Stock Price:

The stock price of Divi's Laboratories Ltd. is affected by various factors such as the company's financial performance, global economic conditions, and market sentiment. Long-term investors can use our pre-built screening tools to track Divi's Laboratories Ltd.'s stock price and identify potential buying opportunities. The stock price of Divi's Laboratories Ltd. has shown a consistent upward trend over the past few years, reflecting the company's strong brand, product portfolio, and customer focus.

Divi''s Laboratories Ltd. Price Chart:

A price chart provides a visual representation of a company's stock price over a period of time. Long-term investors can use our pre-built screening tools to analyze Divi's Laboratories Ltd.'s price chart and identify any trends or patterns. The price chart shows that the stock price of Divi's Laboratories Ltd. has shown a consistent upward trend over the past few years, reflecting the company's strong brand, product portfolio, and customer focus.

Divi''s Laboratories Ltd. News:

Keeping up to date with the latest news about Divi's Laboratories Ltd. is important for investors. Our website provides the latest news about Divi's Laboratories Ltd. from various sources such as financial news websites and social media. Long-term investors can use this information to make informed investment decisions.

Divi''s Laboratories Ltd. Concall:

Divi's Laboratories Ltd. holds conference calls with analysts and investors to discuss its financial performance and future plans. Long-term investors can listen to Divi's Laboratories Ltd.'s concall and use the information provided to make informed investment decisions. Our website provides information about upcoming concalls and links to listen to past concalls.

Divi''s Laboratories Ltd. Transcripts:

Transcripts of Divi's Laboratories Ltd.'s concalls are available on our website. Long-term investors can download the transcripts and use them to analyze the company's financial performance and future plans. The transcripts provide valuable insights into the company's operations and financial performance.

Divi''s Laboratories Ltd. Investor Presentations:

Divi's Laboratories Ltd. provides investor presentations on its website. These presentations provide information about the company's financial performance, strategic initiatives, and future plans. Long-term investors can download Divi's Laboratories Ltd.'s investor presentations from our website and use them to make informed investment decisions. The investor presentations provide valuable insights into the company's operations and financial performance.

Divi''s Laboratories Ltd. Promoters:

Promoters are individuals or entities that have a significant stake in a company. Divi's Laboratories Ltd.'s promoters include Dr. Murali K Divi, Dr. Divi Murali Krishna, and related entities. Long-term investors can use our pre-built screening tools to analyze Divi's Laboratories Ltd.'s promoter holdings and identify any potential conflicts of interest. The promoter holdings of Divi's Laboratories Ltd. are relatively stable, which is a positive sign for long-term investors.

Divi''s Laboratories Ltd. Shareholders:

Divi's Laboratories Ltd. has a large number of shareholders, including institutional investors and individual investors. Long-term investors can use our pre-built screening tools to analyze Divi's Laboratories Ltd.'s shareholder base and identify any potential risks or opportunities. The shareholder base of Divi's Laboratories Ltd. is diverse, which is a positive sign for long-term investors.

Divi''s Laboratories Ltd. Premium Features:

Our website provides premium features tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools can help long-term investors make better investment decisions by providing more detailed insights into the company's financial performance and valuation.

X